Droxidopa

(Northera®)

Droxidopa

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormCapsules (oral: 100 mg, 200 mg, 300 mg)
Drug ClassSynthetic amino acid analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of orthostatic dizziness and light-headedness or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Droxidopa (Northera) is indicated for the treatment of orthostatic dizziness and light-headedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
  • Two studies were reviewed to gather information about this drug.
  • The studies suggest that droxidopa has shown a positive impact on reducing symptoms of postural orthostatic tachycardia syndrome (POTS) and increasing orthostatic tolerance; however, more evidence is needed due to low sample sizes.
  • In terms of treating Orthostatic Hypotension (OH), droxidopa was mentioned as a potential option but without direct comparison regarding its effectiveness against other drugs like clonidine, beta-blockers, midodrine, and pyridostigmine.
  • For both POTS and OH conditions related to autonomic dysfunction such as Parkinson's disease or multiple system atrophy, among others, it appears that the choice between droxidopa or any other medication must consider individual patient profiles, including underlying etiologies and severity, which suggests an emphasis on a personalized medicine approach.
  • While there are no clear conclusions about the superiority or inferiority of Northera compared to other medications used for similar indications, these studies collectively suggest its role within a broader management strategy prioritizing patient quality of life and risk reduction over achieving perfect blood pressure control.

Product Monograph / Prescribing Information

Document TitleYearSource
Northera (droxidopa) prescribing information. 2019Lundbeck, Deerfield, IL

Systematic Reviews / Meta-Analyses